Smith & Nephew (LON:SN) Given Neutral Rating at UBS Group

Key Points

• UBS reiterated a Neutral rating on Smith & Nephew with a GBX 1,300 price target, implying roughly a 13.3% upside from the prior close.
• Analyst consensus is a Hold (2 Buys, 5 Holds) with an average price target of GBX 1,185.86, while RBC recently set a higher target of GBX 1,350.
• The stock opened at GBX 1,147; the company has a market cap of £12.57bn, a P/E of 41.3 and a debt-to-equity ratio of 62.9, reflecting relatively high valuation and leverage.

Smith & Nephew (LON:SN - Get Free Report)'s stock had its "neutral" rating restated by stock analysts at UBS Group in a research report issued to clients and investors on Tuesday,Digital Look reports. They currently have a GBX 1,300 price target on the stock. UBS Group's target price would indicate a potential upside of 13.34% from the company's previous close.

Other equities analysts also recently issued reports about the stock. Berenberg Bank reissued a "hold" rating and issued a GBX 13 price target on shares of Smith & Nephew in a report on Friday. Royal Bank Of Canada restated a "sector perform" rating and issued a GBX 1,350 price objective on shares of Smith & Nephew in a research note on Tuesday, March 17th. Two research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, Smith & Nephew currently has an average rating of "Hold" and an average price target of GBX 1,185.86.

Smith & Nephew Stock Performance

Shares of LON:SN opened at GBX 1,147 on Tuesday. The business has a fifty day moving average of GBX 1,243.05 and a 200-day moving average of GBX 1,260.50. The company has a quick ratio of 0.84, a current ratio of 2.57 and a debt-to-equity ratio of 62.90. The stock has a market cap of £12.57 billion, a P/E ratio of 41.30, a P/E/G ratio of 0.46 and a beta of 0.74.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.